Department of Pediatric Hematology-Oncology, Dana-Farber/Children's Hospital Cancer Center, Boston, MA 02115, USA.
Cancer. 2013 Feb 15;119(4):871-9. doi: 10.1002/cncr.27816. Epub 2012 Sep 12.
Children with cancer in middle-income countries have inferior outcomes compared with similar children in high-income countries. The magnitude and drivers of this survival gap are not well understood. In the current report, the authors sought to describe patterns of clinical presentation, magnitude of treatment abandonment, and survival in children with sarcoma in Central America.
A retrospective review was conducted of hospital-based registries from national pediatric oncology referral centers. Patients with newly diagnosed osteosarcoma, Ewing sarcoma, rhabdomyosarcoma (RMS), and soft tissue sarcoma (STS) between January 1, 2000 and December 31, 2009 were included. Survival analyses were performed first using standard definitions of overall survival (OS) and event-free survival (EFS) and then with abandonment included as an event (abandonment-sensitive OS and abandonment-sensitive EFS).
In total, 785 new cases of pediatric sarcoma were reported (264 diagnoses of osteosarcoma, 175 diagnoses of Ewing sarcoma, 240 diagnoses of RMS, and 106 diagnoses of STS). The rate of metastatic disease at presentation was high (osteosarcoma, 38%; Ewing sarcoma, 39%; RMS, 29%; and STS, 21%). The treatment abandonment rate also was high, particularly among patients with extremity bone sarcomas (osteosarcoma, 30%; Ewing sarcoma, 15%; RMS, 25%; and STS, 15%). Of 559 patients who experienced a first event, 59% had either recurrent or progressive disease. The 4-year OS rate (±standard error) was 40% ± 3%, and the EFS rate was 30% ± 2%; however, these rates decreased further to 31% ± 2% and 24% ± 2%, respectively, when abandonment was taken into account.
The current results indicated that high rates of metastases and treatment abandonment and difficulty with upfront treatment effectiveness are important contributors to the poor survival of children with pediatric sarcomas in Central America. Initiatives for early diagnosis, psychosocial support, quality improvement, and multidisciplinary care are warranted to improve outcomes.
与高收入国家的类似儿童相比,中低收入国家的癌症患儿预后较差。造成这种生存差距的程度和驱动因素尚不清楚。在本报告中,作者旨在描述中美洲肉瘤患儿的临床表现模式、治疗中断的程度以及生存率。
对来自国家儿科肿瘤转诊中心的基于医院的登记处进行了回顾性审查。纳入 2000 年 1 月 1 日至 2009 年 12 月 31 日期间新诊断为骨肉瘤、尤文肉瘤、横纹肌肉瘤(RMS)和软组织肉瘤(STS)的患者。首先使用总体生存(OS)和无事件生存(EFS)的标准定义进行生存分析,然后将放弃治疗作为事件(放弃敏感 OS 和放弃敏感 EFS)进行分析。
共报告了 785 例新的儿童肉瘤病例(264 例骨肉瘤诊断,175 例尤文肉瘤诊断,240 例 RMS 诊断和 106 例 STS 诊断)。就诊时转移性疾病的发生率很高(骨肉瘤为 38%;尤文肉瘤为 39%;RMS 为 29%;STS 为 21%)。治疗中断率也很高,尤其是四肢骨肉瘤患者(骨肉瘤为 30%;尤文肉瘤为 15%;RMS 为 25%;STS 为 15%)。在经历首次事件的 559 例患者中,59%的患者出现了疾病复发或进展。4 年 OS 率(±标准误差)为 40%±3%,EFS 率为 30%±2%;然而,当考虑到放弃治疗时,这些比率分别进一步降至 31%±2%和 24%±2%。
目前的结果表明,高转移率、高治疗中断率以及治疗初期效果不佳是中美洲儿童肉瘤患儿预后较差的重要原因。需要采取早期诊断、社会心理支持、质量改进和多学科护理等措施来改善预后。